Literature DB >> 17283236

Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice.

Yoko Fujiwara1, Masami Hiroyama, Atsushi Sanbe, Junji Yamauchi, Gozoh Tsujimoto, Akito Tanoue.   

Abstract

[Arg8]-vasopressin (AVP) and oxytocin (OT) are neurohypophysial hormones which exert various actions, including the control of blood glucose, in some peripheral tissues. To investigate the type of receptors involved in AVP- and OT-induced glucagon secretion, we investigated the effect of these peptides on glucagon secretion in islets of wild-type (V1bR+/+) and vasopressin V1b receptor knockout (V1bR-/-) mice. AVP-induced glucagon secretion was significantly inhibited by the selective V1b receptor antagonist, SSR149415 (30%), and OT-induced glucagon secretion by the specific OT receptor antagonist, d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH(2)(9)]OVT (CL-14-26) (45%), in islets of V1bR+/+mice. AVP- and OT-induced glucagon secretions were not by the antagonist of each, but co-incubation with both 10(-6) M SSR149415 and 10(-6) M CL-14-26 further inhibited AVP- and OT-induced glucagon secretions in islets of V1bR+/+ mice (57 and 69% of the stimulation values respectively). In addition, both AVP and OT stimulated glucagon secretion with the same efficacy in V1bR-/- mice as in V1bR+/+ mice. AVP- and OT-induced glucagon secretion in V1bR-/- mice was significantly inhibited by CL-14-26. These results demonstrate that V1b receptors can mediate OT-induced glucagon secretion and OT receptors can mediate AVP-induced glucagon secretion in islets from V1bR+/+mice in the presence of a heterologous antagonist, while AVP and OT can stimulate glucagon secretion through the OT receptors in V1bR-/-mice, suggesting that the other receptor can compensate when one receptor is absent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283236     DOI: 10.1677/joe.1.06864

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  9 in total

1.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

2.  Biased Oxytocinergic Modulation of Midbrain Dopamine Systems.

Authors:  Lei Xiao; Michael F Priest; Jordan Nasenbeny; Ting Lu; Yevgenia Kozorovitskiy
Journal:  Neuron       Date:  2017-06-29       Impact factor: 17.173

3.  Metabolic and Kidney Diseases in the Setting of Climate Change, Water Shortage, and Survival Factors.

Authors:  Richard J Johnson; Peter Stenvinkel; Thomas Jensen; Miguel A Lanaspa; Carlos Roncal; Zhilin Song; Lise Bankir; Laura G Sánchez-Lozada
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

4.  Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes.

Authors:  Amal Akour; Violet Kasabri; Nailya Bulatova; Suha Al Muhaissen; Randa Naffa; Hiba Fahmawi; Munther Momani; Ayman Zayed; Yasser Bustanji
Journal:  Rev Diabet Stud       Date:  2018-03-10

Review 5.  Water intake keeps type 2 diabetes away? Focus on copeptin.

Authors:  Giovanna Muscogiuri; Luigi Barrea; Giuseppe Annunziata; Martina Vecchiarini; Francesco Orio; Carolina Di Somma; Annamaria Colao; Silvia Savastano
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

Review 6.  Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery.

Authors:  Zhimin Song; H Elliott Albers
Journal:  Front Neuroendocrinol       Date:  2017-10-18       Impact factor: 8.606

Review 7.  Vasopressin: behavioral roles of an "original" neuropeptide.

Authors:  Heather K Caldwell; Heon-Jin Lee; Abbe H Macbeth; W Scott Young
Journal:  Prog Neurobiol       Date:  2007-11-04       Impact factor: 11.685

Review 8.  The vasopressin Avpr1b receptor: molecular and pharmacological studies.

Authors:  Ja Roper; A-M O'Carroll; Ws Young; Sj Lolait
Journal:  Stress       Date:  2010-09-09       Impact factor: 3.493

9.  Beneficial impact of Ac3IV, an AVP analogue acting specifically at V1a and V1b receptors, on diabetes islet morphology and transdifferentiation of alpha- and beta-cells.

Authors:  Shruti Mohan; Ryan Lafferty; Neil Tanday; Peter R Flatt; R Charlotte Moffett; Nigel Irwin
Journal:  PLoS One       Date:  2021-12-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.